NYSE American - Delayed Quote USD

Matinas BioPharma Holdings, Inc. (MTNB)

0.1789 -0.0026 (-1.43%)
At close: April 26 at 4:00 PM EDT
0.1793 +0.00 (+0.22%)
After hours: April 26 at 7:26 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for MTNB

Recent News: MTNB

View More
Matinas BioPharma Prices $10 Million Registered Direct Offering

Matinas BioPharma Prices $10 Million Registered Direct Offering
GlobeNewswire 24 days ago
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript

Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript
Insider Monkey 26 days ago

Q4 2023 Matinas BioPharma Holdings Inc Earnings Call
Thomson Reuters StreetEvents 30 days ago
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
GlobeNewswire 30 days ago
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
GlobeNewswire last month
Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?

Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?
Benzinga last month
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
GlobeNewswire last month
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
GlobeNewswire last month
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
GlobeNewswire last month
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
GlobeNewswire 2 months ago
Matinas BioPharma to Present at Biotech Showcase 2024

Matinas BioPharma to Present at Biotech Showcase 2024
GlobeNewswire 3 months ago
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
GlobeNewswire 3 months ago
View More

Related Tickers

ACST Acasti Pharma Inc.
2.9000
-2.03%
 
TOVX Theriva Biologics, Inc.
0.4195
+2.33%
 
DARE Daré Bioscience, Inc.
0.3059
+5.77%
 
RNAZ TransCode Therapeutics, Inc.
0.5499
+5.30%
 
TCON TRACON Pharmaceuticals, Inc.
1.8100
+1.12%
 
EQ Equillium, Inc.
1.7100
-5.52%
 
PXMD PaxMedica, Inc.
0.7398
+5.06%
 
RNAC Cartesian Therapeutics, Inc.
21.03
+0.62%
 
KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%
 
KZR Kezar Life Sciences, Inc.
0.8049
+1.89%